Sennosides 7.5mg tablets
Available from a pharmacy with pharmacist advice
Sennosides (also known as senna glycoside or senna) is a medication used to treat constipation[FDA Label][L771] and empty the large intestine before surgery.
Safety information for pregnancy and breastfeeding
Pregnancy
Breastfeeding
Always consult your doctor or midwife before taking any medicine during pregnancy or while breastfeeding. Source: DrugBank (CC BY-NC 4.0).
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
5 branded products available
Part of the Senease brand family (generic: Sennosides)
MHRA licensed products
View all licensed products for Sennosides on the MHRA register
Cenlax 7.5mg tablets 12 Years Plus
Senease Eighteen Years Plus 7.5mg tablets
Senease Twelve Years Plus 7.5mg tablets
Sennosides 7.5mg tablets 12 Years Plus
Sennosides 7.5mg tablets 12 Years Plus
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 14 studies.
Randomised trials: 1 · 2015–2026
Showing all 14 studies, sorted by most relevant.
Nate-Anong B, Khorana J, Chantakhow S, et al.
2025
- Anorectal Malformations
- Sennosides
- Constipation
A. N. Kumar, A. Sneha, K. Srinivas, et al.
Industrial Crops and Products, 2023
Narrowe AB, Lemons JMS, Mahalak KK, et al.
2024
- Gastrointestinal Microbiome
- Anti-Infective Agents
- Drugs, Chinese Herbal
The genus Senna contains globally distributed plant species of which the leaves, roots, and seeds have multiple traditional medicinal and nutritional uses. Notable chemical compounds derived from Senna spp. include sennosides and emodin which have been tested for antimicrobial effects in addition to their known laxative functions. However, studies of the effects of the combined chemical components on intact human gut microbiome communities are lacking. This study evaluated the effects of Juemingzi ( Senna sp.) extract on the human gut microbiome using SIFR ® (Systemic Intestinal Fermentation Research) technology. After a 48-hour human fecal incubation, we measured total bacterial cell density and fermentation products including pH, gas production and concentrations of short chain fatty acids (SCFAs). The initial and post-incubation microbial community structure and functional potential were characterized using shotgun metagenomic sequencing. Juemingzi ( Senna seed) extracts displayed strong, taxon-specific anti-microbial effects as indicated by significant reductions in cell density (40%) and intra-sample community diversity. Members of the Bacteroidota were nearly eliminated over the 48-hour incubation. While generally part of a healthy gut microbiome, specific species of Bacteroides can be pathogenic. The active persistence of the members of the Enterobacteriaceae and selected Actinomycetota despite the reduction in overall cell numbers was demonstrated by increased fermentative outputs including high concentrations of gas and acetate with correspondingly reduced pH. These large-scale shifts in microbial community structure indicate the need for further evaluation of dosages and potential administration with prebiotic or synbiotic supplements. Overall, the very specific effects of these extracts may offer the potential for targeted antimicrobial uses or as a tool in the targeted remodeling of the gut microbiome.
Abstract licence: CC BY
Nagaraja Reddy Rama Reddy, Rucha Harishbhai Mehta, Palak Soni, et al.
PLoS ONE, 2015
- Transcriptome
- Multigene Family
- Senna Extract
Senna (Cassia angustifolia Vahl.) is a world's natural laxative medicinal plant. Laxative properties are due to sennosides (anthraquinone glycosides) natural products. However, little genetic information is available for this species, especially concerning the biosynthetic pathways of sennosides. We present here the transcriptome sequencing of young and mature leaf tissue of Cassia angustifolia using Illumina MiSeq platform that resulted in a total of 6.34 Gb of raw nucleotide sequence. The sequence assembly resulted in 42230 and 37174 transcripts with an average length of 1119 bp and 1467 bp for young and mature leaf, respectively. The transcripts were annotated using NCBI BLAST with 'green plant database (txid 33090)', Swiss Prot, Kyoto Encylcopedia of Genes & Genomes (KEGG), Cluster of Orthologous Gene (COG) and Gene Ontology (GO). Out of the total transcripts, 40138 (95.0%) and 36349 (97.7%) from young and mature leaf, respectively, were annotated by BLASTX against green plant database of NCBI. We used InterProscan to see protein similarity at domain level, a total of 34031 (young leaf) and 32077 (mature leaf) transcripts were annotated against the Pfam domains. All transcripts from young and mature leaf were assigned to 191 KEGG pathways. There were 166 and 159 CDS, respectively, from young and mature leaf involved in metabolism of terpenoids and polyketides. Many CDS encoding enzymes leading to biosynthesis of sennosides were identified. A total of 10,763 CDS differentially expressing in both young and mature leaf libraries of which 2,343 (21.7%) CDS were up-regulated in young compared to mature leaf. Several differentially expressed genes found functionally associated with sennoside biosynthesis. CDS encoding for many CYPs and TF families were identified having probable roles in metabolism of primary as well as secondary metabolites. We developed SSR markers for molecular breeding of senna. We have identified a set of putative genes involved in various secondary metabolite pathways, especially those related to the synthesis of sennosides which will serve as an important platform for public information about gene expression, genomics, and functional genomics in senna.
Abstract licence: CC BY
K. Gowtham, G. Thiruppathi, M. Balasubramanian, et al.
South African Journal of Botany, 2024
José Arias-Rico, Iris Cristal Hernández-Ortega, Osmar Antonio Jaramillo-Morales, et al.
Life, 2025
The objective of this study is to determine the physiological and metabolic effects of administration of dietary fiber formulations to male Wistar rats. The study population was divided into five groups to which food and water were orally administered ad libitum (control), alongside Psyllium plantago, sennosides A and B, cactus pear peel powder, and cactus pear peel tablet powder for 28 days. Body weight, biochemical parameters, fecal moisture, and intestinal transit were determined. The administration of the fiber formulations did not cause differences between the groups and they maintained a healthy weight; however, the consumption of the cactus pear peel tablet powder decreased serum glucose (127.85 ± 5.37 to 68.30 ± 12.48 mg/dL) in rats in a similar form to Psyllium plantago (127.85 ± 5.37 to 96.96 ± 3.26 mg/dL) in comparison with commercial products for rats, and the cactus pear peel powder had lower triglyceride levels (49.52 to 74.44 mg/dL) than commercial products at the end of the treatment. The samples maintained normal HDL levels with the exception of Psyllium plantago that had a decrease in treatment after 28 days. The administration of formulations of dietary fiber of cactus pear peel had physiological and metabolic effects similar to those of commercial products without change in the growth of the animals. Therefore, it could be used in the pharmaceutical or food industry.
Abstract licence: CC BY
Elaheh Zibaee, Maryam Akaberi, Zahra Tayarani-Najaran, et al.
Metabolites, 2023
Senna Mill. (Fabaceae) is an important medicinal plant distributed worldwide. Senna alexandrina (S. alexandrina), the officinal species of the genus, is one of the most well-known herbal medicines traditionally used to treat constipation and digestive diseases. Senna italica (S. italica), another species of the genus, is native to an area ranging from Africa to the Indian subcontinent, including Iran. In Iran, this plant has been used traditionally as a laxative. However, very little phytochemical information and pharmacological reports investigating its safety of use are available. In the current study, we compared LC-ESIMS metabolite profiles of the methanol extract of S. italica with that of S. alexandrina and measured the content of sennosides A and B as the biomarkers in this genus. By this, we were able to examine the feasibility of using S. italica as a laxative agent like S. alexandrina. In addition, the hepatotoxicity of both species was evaluated against HepG2 cancer cell lines using HPLC-based activity profiling to localize the hepatotoxic components and evaluate their safety of use. Interestingly, the results showed that the phytochemical profiles of the plants were similar but with some differences, particularly in their relative contents. Glycosylated flavonoids, anthraquinones, dianthrones, benzochromenones, and benzophenones constituted the main components in both species. Nevertheless, some differences, particularly in the relative amount of some compounds, were observed. According to the LC-MS results, the amounts of sennoside A in S. alexandrina and S. italica were 1.85 ± 0.095% and 1.00 ± 0.38%, respectively. Moreover, the amounts of sennoside B in S. alexandrina and S. italica were 0.41 ± 0.12 % and 0.32 ± 0.17%, respectively. Furthermore, although both extracts showed significant hepatotoxicity at concentrations of 50 and 100 µg/mL, they were almost non-toxic at lower concentrations. Taken together, according to the results, the metabolite profiles of S. italica and S. alexandrina showed many compounds in common. However, further phytochemical, pharmacological, and clinical studies are necessary to examine the efficacy and safety of S. italica as a laxative agent.
Abstract licence: CC BY
Celeste Carolina Patiño Gonzalez, Agostina Fontaine, Marcos Federico Leyba
Journal of Pediatric Surgery Open, 2026
Constipation is a condition affecting children with an estimated prevalence of 9.5–14 %, without gender differences. Its diagnosis is clinical. In some cases, fecal impaction in the rectum produces encopresis or fecal pseudo-incontinence, generating a negative bio-psycho-social impact. While osmotic laxatives like polyethylene glycol (PEG) are the first line of treatment, there are cases refractory to PEG. Stimulant laxatives, such as sennosides, increase colonic motility. The objective of this study is to describe our experience using sennosides for the treatment of constipation in pediatric patients. A retrospective review was conducted on patients treated with sennosides between August 2023 and July 2024. Inclusion criteria: patients aged 1–14 years with idiopathic constipation (Rome IV) or post-surgical constipation (anorectal malformation, Hirschsprung disease). Patients with true fecal incontinence were excluded. A Bowel Management Program was applied with initial disimpaction using enemas followed by daily sennosides (15 mg). Doses were titrated based on response. Therapeutic success (good response) was defined as daily bowel movements, no soiling, and an abdominal radiograph showing no rectal fecal impaction. Twenty-four patients were treated (median age 66 months; 58 % male). Diagnoses included idiopathic constipation (63 %), anorectal malformation (25 %), and Hirschsprung disease (13 %). Seventy-one percent had a history of poor response to PEG. Successful disimpaction with enemas was achieved in 100 % of required cases. Sennoside doses ranged from 7.5 mg to 45 mg. Clinical response was satisfactory in 96 % of patients. Radiological control showed a clean rectum in 58 % and minimal stool in 42 %. Adverse events included one case of perianal dermatitis and one case of blistering (moderate), both resolving with conservative management. Treatment with sennosides is feasible and effective for pediatric patients with constipation refractory to other pharmacological treatments, achieving high therapeutic satisfaction.
Abstract licence: CC BY-NC-ND
Lingling Wang, Shuo Zhao, Jianan Li, et al.
BMC Plant Biology, 2024
- Rheum
- Anthraquinones
- Soil
BACKGROUND: Plant growth and quality are often affected by environmental factors, including geographical location, climate, and soil. In this study, we describe the effect of altitudinal differences on the growth and active ingredients in Rheum tanguticum Maxim. ex Balf. (R. tanguticum), a traditional Chinese medicinal herb known for its laxative properties. RESULTS: The results showed that plants grown at lower altitudes had better growth performances than those in higher altitude areas. The yield varied by 2.45-23.68 times with altitude, reaching a maximum of 102.01 t/ha. In addition, total anthraquinone and total sennoside contents decreased with increasing altitude, whereas total tannins increased with increasing altitude. The total anthraquinone content of the indicator compound reached 5.15% at five experimental sites, which exceeded the Chinese Pharmacopoeia standard by 70.87%. The content of the other two categories of active ingredients reached a maximum value of 0.94% (total sennosides) and 2.65% (total tannins). Redundancy analysis revealed that annual rainfall, annual average temperature, annual sunshine hours, and pH significantly affected growth and active ingredients. Moreover, key metabolites, such as flavonoids, amino acids and their derivatives, phenolic acids, lipids, and terpenes, were differentially expressed between samples from low- and high-altitude cultivation areas. These metabolites were enriched in the flavonoid and flavonol biosynthetic pathway and the monoterpene biosynthetic pathway. CONCLUSIONS: These results suggest that high anthraquinone content was observed in the lowest-latitude cultivation area due to low rainfall and alkaline soil pH. Key metabolites were significantly upregulated in high-latitude cultivation areas. These results provide a scientific basis for quality control and the systematic cultivation of R. tanguticum.
Abstract licence: CC BY
Sarika Chouksey, Sarika Chouksey, Mohd Ashraf Ashfaq, et al.
Frontiers in Plant Science, 2024
Introduction Indian senna ( Senna alexandrina Mill.) (formerly Cassia angustifolia Vahl.) is an important medicinal plant of the family Fabaceae. The leaves and pods of Indian senna yield sennosides and rhein-based laxative. Adulteration of Indian senna is a serious issue as with most of the medicinal plants used in the Indian systems of traditional medicine. The bulk of dried leaves and pods of morphologically related species, such as Cassia fistula , Senna occidentalis , Senna sophera , and Senna tora , is usually mixed with those of the Indian senna, and the admixture is used in laxative-based formulations. The present investigation is a modest attempt at developing species-specific start codon targeted (SCoT) polymorphism- and CAAT-box-derived polymorphism (CBDP)-based sequence-characterized amplified region (SCAR) markers for the identification and authentication of Indian senna and four adulterant species ( C. fistula , S. occidentalis , S. sophera , and S. tora species). Methods In this study, genomic DNA extracted from 44 accessions of Indian senna and four adulterant species was subjected to SCoT and CBDP PCR. The polymorphic amplicons were identified, eluted, ligated, and transformed into Escherichia coli DH5 α strain. PCR, restriction analysis, and DNA sequencing confirmed the transformed recombinant plasmid clones. Results Post-sequencing, the sequence of the primary SCoT and CBDP primers was analyzed and extended into the unique signature sequence of the concerned accessions. This resulted in development of one SCoT-44- and two CBDP-25-based SCARs. SCoT-44 SCAR produced a signature amplicon of 287 bp for accession DCA120, and CBDP-25 SCAR yielded signature amplicons of 575 and 345 bp for accessions DCA13 and DCA119, respectively. The developed SCAR markers were validated across 48 samples (44 accessions of Indian senna and 4 adulterant species) and produced distinct amplicons in Indian senna only, while no such amplicon was observed in the other four adulterant species. Discussion The information generated using these markers have been faithfully converted to single-locus, unequivocal, highly reproducible, and informative sequence-based SCAR markers. These markers will enable discrimination of individual plants on the basis of unique sequence-specific amplicons, which could be used as diagnostic markers to settle issues pertaining to the true identity of Indian senna.
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
0.651h
Mechanism
Sennoside A and B, the components of senna, are metabolized by gut bacteria into…
Food interactions
1 warning
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
10%
[L771]
Half-life
0.651h
[A176990]
Protein binding
[A19235]
Volume of distribution
0.124L/kg
[A176990]
Metabolism
2.6%
[A19239]…
Elimination
3-6%
[L771]…
Clearance
0.007L/h
[A176990]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L771]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 396 interactions
[A19236]
This is normally reversed after 18 hours however chronic use has been shown to be associated with p53 resistance and potential carcinogenicity leading to colon cancer.
[A19236]
The LD50 value in rats was 5000mg/kg. Subacute studies in rats receiving 20mg/kg and dogs receiving 500mg/kg did not produce signs of toxicity.
[A19238]
Tests for mutagenicity and reproductive toxicity do not indicate toxic effects.
[A19238]
Sennosides are not recommended for use in pregnancy due to genotoxic risks associated with chemically similar compounds.
[L771]
The active metabolite of sennosides is excreted in breast milk, though there are no reports of the laxitive effect in breast fed babies.
[L771]
There is no data on the effects of sennosides on fertility.
[L771]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L771]
[A176990]
[A19235]
[A176990]
[A19239]
Sennidins A and B are further metabolized to rheinanthrone DB13175 by gut bacteria using beta-glucosidase.
[A19235]
Rheinanthrone DB13175 is absorbed into systemic circulation where 2.6% is metabolized to rhein DB13174 and sennidins A and B via oxidation.
[A19237][A19248][A19235]
Rheinanthrone DB13175 is the major active metabolite of sennosides A and B which produces the laxative effect of the medication.
[A19235]
Rhein DB13174 is also an active metabolite known to have many protective effects.
[A19247]
[L771]
[A176990]
Proteins and enzymes this drug interacts with in the body
PMID:12239222 PMID:30420639
Could also be permeable to urea (By similarity). Also participates in cell permeability to H2O2 and H2O2-mediated signaling .
PMID:20724658
In skin, transports glycerol to the epidermis and stratum corneum, where it maintains hydration, elasticity, and supports lipid biosynthesis for barrier repair (By similarity). In kidney, contributes to the reabsorption of water, helping the body maintain proper fluid balance (By similarity)
ATC A06AB56
ATC A06AB06
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Sennosides
Additional database identifiers
Drugs Product Database (DPD)
5190
Drugs Product Database (DPD)
8798
ChemSpider
5010
BindingDB
92481
HUGO Gene Nomenclature Committee (HGNC)
HGNC:636
GeneCards
AQP3
Guide to Pharmacology
690
UniProt Accession
AQP3_HUMAN
GenBank Gene Database
U28646
GenBank Protein Database
896047
UniProt Accession
Q72547_HV1
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Molecular structure

ATC classifications (Wikidata)
Linked open data from Wikidata (Q502327), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. Molecular structure images from Wikimedia Commons.